AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 80, Issue 1 50-53, Copyright © 1990 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Facklam, D P
Right arrow Articles by Westland, M M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Facklam, D P
Right arrow Articles by Westland, M M
An epidemiologic postmarketing surveillance study of prescription acne medications.

D P Facklam, J S Gardner, G L Neidert and M M Westland

Medication Monitoring Program, Upjohn Company, Kalamazoo, MI 49001.

After the Food and Drug Administration approved a topical antibiotic for the treatment of acne, we began a postmarketing surveillance study to measure the frequency of antibiotic-associated colitis and diarrhea in acne patients treated with topical antibiotics and low doses of oral antibiotics. Pharmacists recruited 13,465 patients who presented a prescription for an acne medication, and we obtained detailed information on the use of the medications, perceived acceptability, and the occurrence of new health events from 6,453 with computer-assisted telephone interviews. Three cases (less than 0.1%) of antibiotic-associated diarrhea and one case (less than 0.1%) of antibiotic-associated colitis were confirmed. We conclude that this methodology can provide further information about the safety of a drug once it is in customary use, at a fraction of the cost of Phase III clinical trials.




This article has been cited by other articles:


Home page
 Med Decis MakingHome page
F. Alemi, R. Stephens, T. Parran, S. Llorens, P. Bhatt, A. Ghadiri, and E. Eisenstein
Automated Monitoring of Outcomes: Application to Treatment of Drug Abuse
Med Decis Making, April 1, 1994; 14(2): 180 - 187.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Public Health Association